

Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myeloid leukemia acute | D015470 | — | C92.0 | 1 | 2 | — | — | — | 3 |
| Leukemia | D007938 | — | C95 | 1 | 1 | — | — | — | 2 |
| Myeloid leukemia | D007951 | — | C92 | 1 | 1 | — | — | — | 2 |
| Hematopoietic stem cell transplantation | D018380 | — | — | — | 1 | — | — | — | 1 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Myelodysplastic syndromes | D009190 | — | D46 | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia chronic | D015477 | — | C93.1 | 1 | — | — | — | — | 1 |
| Myelomonocytic leukemia juvenile | D054429 | — | C93.3 | 1 | — | — | — | — | 1 |
| Drug common name | BISANTRENE |
| INN | bisantrene |
| Description | Bisantrene is a hydrazone resulting from the formal condensation of both of the aldehyde groups of anthracene-9,10-dicarbaldehyde with 2-hydrazinyl-4,5-dihydro-1H-imidazole. It has a role as an antineoplastic agent. It is a hydrazone, a member of imidazolidines and a member of anthracenes. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) | ![]() |
| Structure (InChI/SMILES or Protein Sequence) | C(=N/NC1=NCCN1)\c1c2ccccc2c(/C=N/NC2=NCCN2)c2ccccc12 |
| PDB | — |
| CAS-ID | 78186-34-2 |
| RxCUI | — |
| ChEMBL ID | CHEMBL25336 |
| ChEBI ID | — |
| PubChem CID | 51323 |
| DrugBank | — |
| UNII ID | 39C34M111K (ChemIDplus, GSRS) |
